Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Cutaneous Melanocytic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Melanocytic Neoplasm
Cutaneous Melanocytic Neoplasm

Cancer Family

Cutaneous Melanocytic Neoplasm

CI-CAN-00000154Explore in graph →

Non-malignant81 active trials1 approved drugs61 evidence items

NCIt: C7161

Overview
Statistics
Survival
Genomics14
Variants & evidence61
Drugs29
Trials254
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (83)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 51–75 of 83 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
· Lancet Oncol · 2012 · PMID 22805292 · validated civic_curation pubmed
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
· Clin Cancer Res · 2016 · PMID 26307133 · validated civic_curation pubmed
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
· Cancer Discov · 2013 · PMID 23288408 · validated civic_curation pubmed
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
· N Engl J Med · 2016 · PMID 27433843 · validated civic_curation pubmed
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.
· Nature · 2015 · PMID 26444240 · validated civic_curation pubmed
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
· Cancer Discov · 2012 · PMID 22798288 · validated civic_curation pubmed
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.
· Melanoma Res · 2014 · PMID 24933606 · validated civic_curation pubmed

Showing 51–75 of 83 publications

← Previous
1
2
3
4
Next →

Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.

· Oncologist · 2025 · PMID 39504576 · validated civic_curation pubmed

Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma.

· Oncologist · 2024 · PMID 38470950 · validated civic_curation pubmed

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

· J Clin Oncol · 2008 · PMID 18390968 · validated civic_curation pubmed

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.

· Ann Oncol · 2014 · PMID 24504448 · validated civic_curation pubmed

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.

· Pigment Cell Melanoma Res · 2015 · PMID 26072686 · validated civic_curation pubmed

A pediatric case of pigmented epithelioid melanocytoma with chromosomal copy number alterations in 15q and 17q and a novel NTRK3-SCAPER gene fusion.

· J Cutan Pathol · 2020 · PMID 31437301 · validated civic_curation pubmed

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

· Cancer Discov · 2014 · PMID 24265153 · validated cbioportal_study pubmed

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

· Clin Cancer Res · 2013 · PMID 24345920 · validated civic_curation pubmed

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

· Pigment Cell Melanoma Res · 2014 · PMID 24495407 · validated civic_curation pubmed

Elucidating distinct roles for NF1 in melanomagenesis.

· Cancer Discov · 2013 · PMID 23171796 · validated civic_curation pubmed

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.

· Oncogene · 2009 · PMID 18794803 · validated civic_curation pubmed

The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.

· Melanoma Res · 2003 · PMID 12777976 · validated civic_curation pubmed

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

· PLoS One · 2011 · PMID 22194965 · validated civic_curation pubmed

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.

· Oncotarget · 2015 · PMID 26304929 · validated civic_curation pubmed

Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.

· Melanoma Res · 2014 · PMID 24950457 · validated civic_curation pubmed

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

· Cell · 2010 · PMID 20141835 · validated civic_curation pubmed

Shain et al. Nat Genet 2015

· 2015 · PMID 26343386 · validated cbioportal_study pubmed

Alexander N et al. Clin Cancer Res 2021

· 2021 · PMID 33509808 · validated cbioportal_study pubmed